GILD · Full Picture

GILEAD SCIENCES, INC. — the full picture

Earnings window · 2026-08-06 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 88
    -132.1% operating_income; 3 sources (news, sec_filing, transcript); 3 forward row(s); structured_verified
    Gilead expected approximately $12.9 billion of acquired IPR&D expenses, including $1.4 billion in upfront payments expected in the fourth quarter for the PepStar Therapeutics acquisition and Vir collaboration.
  2. Acquisition-Related R&D Charges · M&A and divestituresPriority 85
    -135.1% operating_income; 2 sources (news, press_release); 2 forward row(s); quote_verified
    Gilead’s 2026 GAAP and non-GAAP diluted loss per share guidance includes an approximately $9.88 per-share impact from $12.4 billion of acquired IPR&D charges related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions announced in 2026, net of the Lakefront collaboration impact and related taxes.
  3. Liquidity and Cash Position · Liquidity & cash positionPriority 83
    -17.4% cash (realized); 2 sources (press_release, sec_filing); structured_verified
    Gilead’s cash and marketable debt securities declined primarily due to year-to-date acquisition outflows of $11.3 billion, debt repayments of $2.8 billion, dividends of $3.1 billion and stock repurchases of $1.1 billion, partially offset by $11.2 billion of operating cash flow and $4.1 billion of net debt-financing proceeds.
  4. Research Investment and Capacity · UnclassifiedPriority 80
    +55.1% assets; 2 sources (news, press_release); 2 forward row(s); quote_verified
    Gilead opened a new Research Center to expand oncology, inflammation and research data science capabilities; it is the first of three projects supporting a $32 billion U.S. research, development and manufacturing investment through 2030.
  5. Operating Expense Trends · Operating expenses (SG&A)Priority 75
    -7.7% operating_income (realized); 3 sources (press_release, sec_filing, transcript); 2 forward row(s); structured_verified
    Gilead’s third-quarter 2026 R&D expenses and non-GAAP R&D expenses increased to $1.6 billion from $1.3 billion year over year, primarily driven by higher employee-related and clinical materials costs.
  6. Guidance and Outlook · Guidance & outlookPriority 72
    3 sources (news, press_release, transcript); 5 forward row(s); quote_verified
    Gilead raised its 2026 base business sales guidance to $30.7 billion-$31.0 billion, up $900 million at the midpoint from August guidance and $1.65 billion at the midpoint from initial 2026 guidance.
  7. In-Process R&D Impairment · Restructuring & impairmentPriority 72
    -21.1% operating_income (realized); structured_verified
    Gilead and Merck discontinued the Phase 3 EVOKE-03 study of Trodelvy plus Keytruda for first-line metastatic NSCLC with high PD-L1 expression (TPS ≥50%), following the external Data Monitoring Committee’s recommendation after review of progression-free survival and interim overall survival analyses.
  8. HIV and PrEP Demand Growth · Demand, orders & backlogPriority 70
    4 sources (news, press_release, sec_filing, transcript); quote_verified
    Gilead’s third-quarter 2026 Descovy sales increased 49% to $1.0 billion year over year, primarily driven by higher average realized price and favorable inventory dynamics.
  9. Oncology Pipeline Progress · Products & launchesPriority 70
    3 sources (news, sec_filing, transcript); 6 forward row(s); quote_verified
    Gilead's application for monthly oral HIV treatment candidate 3107 was on clinical hold because of unexpected metabolite effects, and the company was working through the hold while developing backup molecules.
  10. Acquisition and Restructuring · UnclassifiedPriority 69
    -12.1% operating_income (realized); structured_verified
    Gilead incurred $11.3 billion of acquired IPR&D expenses for the nine months ended September 30, 2026, primarily including $7.0 billion for Arcellx, $3.1 billion for Tubulis, $1.0 billion for Ouro Medicines and $80 million for the Suzhou Genhouse collaboration.
  11. In-Process R&D Impairment · UnclassifiedPriority 69
    -22.4% operating_income (realized); structured_verified
    In-process research and development impairment charge of $1.75 billion recognized in the three months ended June 30, 2026 related to the NSCLC IPR&D intangible asset following discontinuation of the Phase 3 EVOKE-03 study.
  12. Quarterly Dividend Declaration · Buybacks & dividendsPriority 68
    2 sources (news, sec_filing); 2 forward row(s); quote_verified
    In October 2026, Gilead’s board declared a quarterly dividend of $0.82 per common share, payable December 30, 2026, to stockholders of record at close of business December 15, 2026.

Threads by pillar

Revenue & Demand Priority 88 · 9 threads

Costs & Margins Priority 89 · 5 threads

Capital & Balance Sheet Priority 90 · 5 threads

Strategy & Portfolio Priority 95 · 11 threads

Legal, Regulatory & Policy Priority 59 · 6 threads

Guidance & Outlook Priority 72 · 1 thread

Macro & Market Conditions Priority 54 · 2 threads

Shareholders & Street Priority 30 · 1 thread

Unclassified Priority 96 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-267.3%+267.3%-356.4%
cash-57.5%+57.5%-17.6%
assets+57.3%+57.3%-3.5%
revenue-1.4%+1.4%-1.6%
liability-0.9%+0.9%—
net_income——-172.2%